United Capital Management of KS Inc. Purchases Shares of 30,343 Pfizer Inc. (PFE)

United Capital Management of KS Inc. purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the third quarter, Holdings Channel reports. The firm purchased 30,343 shares of the biopharmaceutical company’s stock, valued at approximately $1,313,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Naples Global Advisors LLC grew its position in shares of Pfizer by 5.4% in the second quarter. Naples Global Advisors LLC now owns 33,695 shares of the biopharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 1,712 shares during the last quarter. Steward Partners Investment Advisory LLC grew its position in Pfizer by 25.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 285,325 shares of the biopharmaceutical company’s stock worth $10,352,000 after buying an additional 57,176 shares in the last quarter. Destination Wealth Management grew its position in Pfizer by 962,667.3% during the second quarter. Destination Wealth Management now owns 500,639 shares of the biopharmaceutical company’s stock worth $18,163,000 after buying an additional 500,587 shares in the last quarter. Sterling Capital Management LLC grew its position in Pfizer by 16.6% during the second quarter. Sterling Capital Management LLC now owns 2,478,848 shares of the biopharmaceutical company’s stock worth $89,933,000 after buying an additional 353,212 shares in the last quarter. Finally, Pennsylvania Trust Co grew its position in Pfizer by 10.9% during the second quarter. Pennsylvania Trust Co now owns 681,255 shares of the biopharmaceutical company’s stock worth $28,127,000 after buying an additional 67,151 shares in the last quarter. 69.30% of the stock is currently owned by hedge funds and other institutional investors.

In other Pfizer news, major shareholder Pfizer Inc bought 55,556 shares of the business’s stock in a transaction on Monday, October 15th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $1,000,008.00. Following the completion of the purchase, the insider now directly owns 21,976,484 shares of the company’s stock, valued at $395,576,712. The acquisition was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

A number of equities research analysts recently issued reports on PFE shares. Cantor Fitzgerald reissued a “buy” rating and set a $53.00 price target on shares of Pfizer in a research report on Wednesday, October 17th. Barclays set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Friday, October 19th. Morgan Stanley set a $45.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Thursday, September 13th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, October 30th. Finally, Credit Suisse Group set a $40.00 price target on Pfizer and gave the stock a “hold” rating in a research report on Sunday, October 14th. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $43.41.

NYSE PFE opened at $43.80 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a fifty-two week low of $33.20 and a fifty-two week high of $46.47. The firm has a market cap of $260.74 billion, a price-to-earnings ratio of 14.70, a price-to-earnings-growth ratio of 2.18 and a beta of 0.88.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.03. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The firm had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. During the same period in the prior year, the company earned $0.67 earnings per share. The company’s quarterly revenue was up 1.0% on a year-over-year basis. As a group, analysts predict that Pfizer Inc. will post 3 EPS for the current fiscal year.

Pfizer declared that its Board of Directors has approved a share buyback plan on Friday, December 14th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to purchase up to 3.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board believes its shares are undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Shareholders of record on Friday, February 1st will be paid a dividend of $0.36 per share. This is a boost from Pfizer’s previous quarterly dividend of $0.34. This represents a $1.44 annualized dividend and a yield of 3.29%. Pfizer’s dividend payout ratio is presently 51.32%.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.com-unik.info/2018/12/16/united-capital-management-of-ks-inc-purchases-shares-of-30343-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: How interest rates affect municipal bond prices

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit